All In Biotech

Drug Trial Radar · NCT00659971

Phase 2B Dose-Ranging Study of PAC113 Mouthrinse in HIV Seropositive Individuals With Oral Candidiasis

A Phase 2B Dose-Ranging Study of PAC113 Mouthrinse for Clinical and Microbial Evaluation in HIV Seropositive Individuals With Oral Candidiasis to Establish the Optimal Dose of PAC113

Last checked: Nov 19, 2026Latest source record: Jun 26, 2008 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 223 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

223

Actual

Start

Jan 2008

Primary completion

Jun 2008

Study completion Jun 2008

Sponsor

Sponsor type
Industry
Collaborators
Quintiles, Inc.
First posted
Apr 17, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the optimal dose of PAC113 mouthrinse for treatment of oral candidiasis in HIV seropositive patients.

Conditions

  • Oral Candidiasis

Interventions

  • PAC113Drug

    PAC113 mouthrinse 0.15%; 0.075%; 0.0375% QID for 14 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Eliminating or reducing clinical signs and symptoms of oral Candida infections.Time frame: Day 19

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Rosedale Infectious Disease

    Huntersville, North Carolina

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.